Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Drugs Dermatol ; 23(6): e144-e148, 2024 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-38834228

RESUMO

Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile. J Drugs Dermatol. 2024;23(6):e144-e148. doi:10.36849/JDD.8258e.


Assuntos
Anticorpos Monoclonais Humanizados , Penfigoide Bolhoso , Prurido , Humanos , Penfigoide Bolhoso/tratamento farmacológico , Penfigoide Bolhoso/diagnóstico , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , Estudos Retrospectivos , Feminino , Masculino , Idoso , Pessoa de Meia-Idade , Resultado do Tratamento , Idoso de 80 Anos ou mais , Prurido/tratamento farmacológico , Prurido/etiologia , Prurido/diagnóstico , Adulto , Reação no Local da Injeção/etiologia , Reação no Local da Injeção/diagnóstico
2.
Inorg Chem ; 61(35): 13836-13845, 2022 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-36007248

RESUMO

Single-phase MxCs (M = Fe, Co, and Ni) were prepared by solvothermal conversion of Prussian blue single source precursors. The single source precursor is prepared in water, and the conversion process is carried out in alkylamines at reaction temperatures above 200 °C. The reaction is scalable using a commercial source of Fe-PB. High-resolution transmission electron microscopy, X-ray photoelectron microscopy, and powder X-ray diffraction confirm that carbides have thin oxide termination but lack graphitic surfaces. Electrocatalytic activity reveals that Fe3C and Co2C are oxygen evolution reaction electrocatalysts, while Ni3C is a bifunctional [OER and hydrogen evolution reaction (HER)] electrocatalyst.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA